TPOXX Financial by other the to be update, and for fourth an Officer; I thank work as with contributions happy our Phil to organization, and behalf our everyone, Chief and the into am contributions recognizing was afternoon, Good and strong franchise. of questions.
I'd SIGA On you want thank many to Luckshire, Dan update his to our opportunity CEO year years. XXXX. we're commercial securing our results Phil joined more full it by team, review joining sales business this key to pleased for Gomez, for making any in and the company quarter like we'll who X begin of company I our to of Phil call the a our SIGA's served the over and of approvals answer instrumental today. XX have transforming provide shareholders. After to in for regulatory today's is countries for
note, passion and SIGA's this our for our leverage I'm patients, as and advancement help personal on role X excited organization. to deep-seated for successful benefit as shareholders. worldwide. building to CEO. and greater therapies to available join fulfill I'm SIGA success driving the scientific experience extremely a in nearly and addressing of and growth experience decades the leading I Having take an commercial essential spent have unmet on forward look multibillion-dollar excited customers of focused needs a have care, I well On health on SIGA's innovation, potential extensive to
team the maintained profitable share this has the belief for SIGA's commercial is is activities, management a and R&D has highly relations. strong It in future. operational my that to a and company, week fully pleased been for only distinguishing This a deep grounded supply First, customers. This in our business a the fundamentals. U.S.-based antiviral following: company SIGA with built And government is belief integrated Although bright has asset with I'm expertise company has chain. sixth my
is value franchise track of Again, years. is which securing that product in point a speaks XX TPOXX Second, past of foundational a a have government record contracts, $X and TPOXX. over the of has significant multiyear totaled to distinction the billion this
best-in-class has financial Third, SIGA performance. achieved
million. achieved, annual sheet. pretax Our income $XX while past have results the been a operating average strong maintaining been years These over balance has X
Fourth, SIGA has attractive growth opportunity.
Let me indications potential an like to TPOXX, expand programs update later these few. a mention the remarks. the call mpox. term, of In near I'll has prophylaxis, post-exposure which to include little on in just a and to these provide we the PEP SIGA
risk the risk. to a a expand fully with and orthopox protection orthopox the viruses. in ensure of view against governments has virus term, for range across to the full preparedness tools work Also near geographically modernized and world, stockpiling and We SIGA the embrace have opportunity of governments want the to for
with thinking capabilities into best-in-class are more capabilities. care. And has government and we can strong leverage therapeutic broadly, to procurement We believe that complementary SIGA antiviral areas patient these points move of similar
and level and leadership highest the officious us to government R&D experience among measures. all enables in TPOXX' disease public of and contracting reinforced common innovation commercial has this expertise individual Importantly, execution, of SIGA's safety. support
I well-positioned factors, SIGA believe of these is performance shareholders. for further our strong X critical innovation, for attractive value result business and a As creation
Stockpile XXXX. of the XX% coming governments. the XXXX SNS, strong. achieved X and X million, a that Strategic achieved are $XXX the we increase sources of highest over in international very National revenues U.S. Defense am reflects revenues full the including the finished million the our to year diversity U.S. were past of quarter, year Full from or amounts product the over turning fourth a pleased $XXX Now I product the Approximately Department report year financial of results. years. to This
operating $XX increase our Dan a the a details of and on resilience was shortly. is million team, of testament XXXX. over results Pretax This income XXXX, our to franchise more these approximately provide will the in company. SIGA value strength the XX% of the
of has paid capital to management declared This Additionally, the special pleased in cash in And we paid we XXXX. XX% Board per a spent share of dividend, June of that special dividend share $XX XXXX, Directors be a combination of and increase to $X.XX dividend special through on April. I'm represents million a announce buyback. our in over
demonstrates This of confidence strength our financial team, company the future. Board the the management our have and the and in
in a record, with for track and both term. and proven short with both Our SNS compelling contract long-term new coupled company attractive backdrop potential the the of a longer our provides
plan business. to we to grow on forward, continuing our Looking invest
maintaining and for earnings goal value While revenues our balanced capital allocation growth creating strong and and approach, shareholders. a the long-term delivering with disciplined of
TPOXX about the And mpox on that I for for have will additional last prophylactic Based for studies call. humans any TPOXX' was not efficacy to prove PEP situation. in but and I benefits what now safety PEP, investor in conducted, by treatment extended start would With The of for studies XX a the the regard PEP, reported been FDA on we data days. like has and asked for programs. believe patients to recapping to talk has trials asked
safety studies. consistent We have completed this with the is requirement and prior data
the It not existing strong is serious TPOXX' trial drug-related with Consistent clinical safety profile. adverse show any events. to results do emphasize important
solely on have Because a small to trial, an in a Jynneos we of used In TPOXX an trial, response. evaluate event the treatment addition immunogenicity TPOXX completed likely the in to vaccine. outbreak, to immune safety would combination impact TPOXX as has be pox vaccine with
on difference did consistent expected, what vaccine, trial, Jynneos between vaccine, of TPOXX. results the to received the data while while on immunogenicity that from those receive immunogenicity those we who meaningful preliminary analysis with the the placebo, the compared In a show of the Jynneos not
that previously, the However, measurable group number to in mentioned the than indicated response Jynneos the volunteers who was vaccine, TPOXX and immune lower as placebo had expected. both the of results
to for originally results, deemed the which statistical the the the non-inferior as study. these was data in assess difficult planned endpoint determination, Given necessary for primary
colleagues the On on the a to CDC, validated expected and reported responses. TPOXX the call, them. also performed show their Jynneos trial at sent samples print that the immune last of were investor immunogenicity analysis we our subset samples who These the from
given the prior analysis the associated getting by with working As the challenges now our such, set are we reanalyze, on of vendor. conducted the CRO entire samples
We believe path prior the unexpected forward analyses nature CDC preliminary these provide the potential of results. a despite
working are NDA XX supplemental the As towards such, a months. submission in next we within parallel,
in grateful best are colleagues this action, course on at have of have FDA forward. timely believe the as to and of our the We objections. the data efficient path is any plans not agrees We CDC and briefed from immunogenicity the been our getting this for collaboration terms they and trial, voiced
to efficacy on immune immunogenicity not it is vaccine reduce an nor TPOXX' showing that on be they TPOXX But TPOXX smallpox, the patient relevance safety those for mortality the with the study as the impact or a final PEP program, the immunogenicity population mpox about the to are safety. emphasize of use without or sacrificing response. in Rather, the important the about an analysis epidemic, who and are I case individuals the of will PEP, be that of comment virus of of morbidity are want orthopox
which like would shift data studies continue I provide involving trials, some TPOXX, provide data quick to as current Now the update controlled and a to specific gears X to points. patients multiple well studies. as includes on randomized mpox enroll observational trials and collect These
were PALM noted Africa, conducted has NIAID Africa. as continue the which increases enrolled demonstrate in last A from increase also NIAID the patient approximately call. our counts there our STOMP in the as substantial XXX In in XXX call. XXX case February, to These the noted in increase accumulate patients, trial that patients. is In last DRC, numbers especially in of trial, patients, February, of patients the large from XXX a being
a glimpse. they provide Importantly, also
by would risk warning Some global viruses. a overall posed say into health the orthopox
are working to demonstrate agencies treating and TPOXX and parts other randomized whether in is effective world the trial to like the patients would safe health achieve outcome and of best other clinical the the Europe for remind, for to approved complications we from for mpox on with such, As possible is perspective. NIH U.S. health mpox closely cowpox in the in U.K. and vaccinia a and I TPOXX smallpox, mpox, however, public Africa,
At I Dan to the turn point, would over like for update. financial the to call this
